|
|
|
| Analysis of drug use rule of Chinese herbal compound prescription in the treatment of herpes zoster based on national patent |
| WANG Zixuan1 DAN Wenchao1 LI Bin2 ZHANG Guangzhong1 |
1.Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, China;
2.Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, China |
|
|
|
Abstract Objective To analyze the drug use rule of Chinese herbal compound prescription in the treatment of herpes zoster based on data mining, and to provide reference for clinical treatment. Methods Through searching the patent database of the State Intellectual Property Office, the patents of Chinese herbal compound prescription for treating herpes zoster from January 2001 to September 2021 were obtained, and the prescription database was established for drug frequency statistics and analysis of the nature and flavor, channel tropism, and efficacy of Chinese herbal. After modeling, the Apriori association rule analysis and system cluster analysis were implemented, and the core complex network of Chinese herbal co-occurrence was constructed by Python. Results A total of 179 Chinese herbal compound prescription patents were included, involving 507 drug flavors, and the proportion of high-frequency drugs was the highest for heat-clearing drugs. Among four nature of drugs, cold was the most common, followed by warm. The five flavours were bitter, followed by sweet and pungent. Liver channel is the main channel. Common couplet medicines included Plantaginis Semen-Bupleuri Radix, Olibanum-Myrrha, etc., and the three herb drug combinations included Isatidis Radix-Bupleuri Radix-Glycyrrhizae Radix Et Rhizoma, Plantaginis Semen-Gentianae Radix Et Rhizoma-Bupleuri Radix, Coptidis Rhizoma-Forsythiae Fructus-Lonicerae Japonicae Flos, etc. Traditional Chinese medicines with frequency > 30 were divided into six groups by systematic cluster analysis. Conclusion There are rules to follow in the treatment of herpes zoster with national Chinese herbal compound prescription patent, and the purpose is to “clear heat, promote diuresis, remove toxicity substance, regulate qi, promote blood, and relieve pain”, which accords with the theoretical basis of traditional Chinese medicine in treatment of herpes zoster.
|
|
|
|
|
|
[1] 中国医师协会皮肤科医师分会带状疱疹专家共识工作组.带状疱疹中国专家共识[J].中华皮肤科杂志，2018，51（6）：403-408.
[2] 周冬梅，陈维文.蛇串疮中医诊疗指南（2014年修订版）[J].中医杂志，2015，56（13）：1163-1168.
[3] 但文超，刘子彰，何庆勇，等.基于国家专利的中药复方干预慢性胆囊炎的数据挖掘研究[J].世界科学技术-中医药现代化，2021，23（6）：2043-2050.
[4] 国家药典委员会.中华人民共和国药典[S]一部.北京：中国医药科技出版社，2020.
[5] 程宏斌，伍景平，王岷珉.从中医古籍角度试论蛇串疮病因病机[J].四川中医，2016，34（10）：21-22.
[6] 刘星显.237例带状疱疹住院病例临床特点及中医证型分布规律研究[D].广州：广州中医药大学，2021.
[7] 吴玲芳，李雨桐，唐迎紫，等.芍药甘草汤化学成分及药理作用研究进展[J].药物评价研究，2021，44（6）：1354- 1360.
[8] 冯利梅.芍药甘草汤治疗神经病理性疼痛的物质基础与作用机制研究[D].咸阳：陕西中医药大学，2021.
[9] 常成，宋燕.甘草酸铵对带状疱疹后遗神经痛大鼠GLP- 1R/IL-10/β-内啡肽通路及脊髓背角小胶质细胞活化的影响[J].免疫学杂志，2022，38（1）：81-87.
[10] 周银平.芍药甘草汤治疗带状疱疹后遗神经痛的临床疗效及其安全性[J].临床合理用药杂志，2021，14（15）：127-129.
[11] 江楠，于靖，杨莉，等.中药柴胡皂苷药理作用的研究进展[J].环球中医药，2018，11（5）：796-800.
[12] 刘于媛.小柴胡汤加味治疗肝脾失和证带状疱疹后神经痛临床研究[D].昆明：云南中医药大学，2021.
[13] 宋春红，葛庆芳，张惠云.舒郁胶囊对大鼠海马神经元5-HT3R激活后Ca2+的影响[J].山东中医药大学学报，2014，38（3）：263-265.
[14] 牟君杰.黄芩素抗水痘—带状疱疹病毒感染的体外研究[D].大连：大连医科大学，2018.
[15] 王佳，孙桂芹，马丽俐.复方黄芩溶液湿敷治疗带状疱疹疗效观察[J].浙江中医药大学学报，2016，40（2）：134- 136，149.
[16] 封桂英.黄芩茎叶总黄酮对CIA小鼠细胞免疫功能的影响[D].承德：承德医学院，2013.
[17] 张美芳，董岩.抑制作用的实验研究[J].齐鲁医学杂志，2003（2）：156-157.
[18] 王剑，侯林，陈亚乔，等.金银花多糖的提取纯化及抗病毒活性研究[J].中国医院药学杂志，2018，38（8）：810- 812.
[19] 杨亚勤.板蓝根药理作用及临床应用研究[J].中国继续医学教育，2015，7（3）：252.
[20] 邓福华，王井泉，周猜.延胡止痛方治疗带状疱疹后遗神经痛疗效观察[J].深圳中西医结合杂志，2021，31（15）：62-64.
[21] 马琳，卢芳.老年带状疱疹药物治疗的对比观察[J].中成药，2017，39（8）：1758-1760.
[22] 严明月，黎颖佳，陈缘缘，等.基于数据挖掘探讨中医药治疗带状疱疹后遗神经痛的用药规律[J].中国医药导报，2022，19（10）：127-130.
[23] 杨星兴，李丽桂，谢蔷薇，等.渗湿益气活血汤配合电针治疗老年带状疱疹后遗神经痛的临床效果[J].中国医药科学，2021，11（2）：75-77，124.
[24] 张琴，林少健.陈汉章教授从肝论治皮肤病经验撷菁[J].中医药导报，2018，24（1）：113-115.
[25] 张艳菊，李董，张凤瑞，等.一分为三解析刘复兴教授从心论治蛇串疮经验[J].云南中医中药杂志，2017，38（8）：5-8.
[26] 顾东彦，王子雯，许孟月，等.刘学伟教授治疗蛇串疮经验[J].中医临床研究，2022，14（1）：93-94. |
|
|
|
